[1]郑紫恒),周英发),任景丽),等.hMLH1、hMSH2、hMSH6在中青年散发性结直肠癌中的表达及对预后的影响[J].郑州大学学报(医学版),2018,(02):165-170.[doi:10.13705/j.issn.1671-6825.2017.07.50]
 ZHENG Ziheng),ZHOU Yingfa),REN Jingli),et al.Expressions of hMLH1,hMSH2 and hMSH6 in young and middle-aged patients with sporadic colorectal cancer and its effect on prognosis[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(02):165-170.[doi:10.13705/j.issn.1671-6825.2017.07.50]
点击复制

hMLH1、hMSH2、hMSH6在中青年散发性结直肠癌中的表达及对预后的影响()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2018年02期
页码:
165-170
栏目:
论著
出版日期:
2018-03-20

文章信息/Info

Title:
Expressions of hMLH1,hMSH2 and hMSH6 in young and middle-aged patients with sporadic colorectal cancer and its effect on prognosis
作者:
郑紫恒1)周英发1)任景丽2)贾萌萌1)黄丽娜1)刘淑红1)农文志1)
1)郑州大学第二附属医院消化内科 郑州 450014
2)郑州大学第二附属医院病理科 郑州 450014
Author(s):
ZHENG Ziheng1)ZHOU Yingfa1)REN Jingli2)JIA Mengmeng1)HUANG Lina1)LIU Shuhong1)NONG Wenzhi1)
1)Department of Gastroenterology,the Second Affiliated Hospital,Zhengzhou University,Zhengzhou 450014
2)Department of Pathology,the Second Affiliated Hospital,Zhengzhou University,Zhengzhou 450014
关键词:
错配修复蛋白 结直肠癌 病理特征 预后
Keywords:
mismatch repair protein colorectal carcinoma pathological characteristics prognosis
分类号:
R735.3
DOI:
10.13705/j.issn.1671-6825.2017.07.50
摘要:
目的:探讨hMLH1、hMSH2、hMSH6在中青年散发性结直肠癌(SCC)中的表达及对预后的影响。方法:采用免疫组化法检测96例中青年SCC组织中hMLH1、hMSH2、hMSH6的表达情况,分析这3种错配修复蛋白(MMR)表达缺失与患者临床病理特征及预后的关系。结果:hMLH1的表达缺失率为20.8%(20/96),hMSH2的表达缺失率为8.3%(8/96),hMSH6的表达缺失率为7.3%(7/96),MMR总表达缺失率为28.1%(27/96)。MMR表达缺失在pTNM分期、肿瘤部位、肿瘤直径、淋巴结转移和大体类型间的差异均有统计学意义(P<0.05)。MMR表达缺失组的5 a无病生存率为77.8%(21/27),高于MMR正常组46.4%(32/69),差异有统计学意义(χ2=8.955,P=0.003)。MMR表达缺失组的5 a总生存率为85.2%(23/27),高于MMR正常组49.3%(34/69),差异有统计学意义(χ2=12.009,P<0.001)。单因素和多因素分析显示,MMR状态是影响SCC患者无病生存时间和总生存时间的危险因素。结论:中青年SCC患者MMR表达缺失组患者较MMR正常组患者预后好。
Abstract:
Aim: To discuss expressions of hMLH1, hMSH2 and hMSH6 protein in the young and middle-aged patients with sporadic colorectal carcinoma(SCC)and their effects on prognosis.Methods: Immunohistochemistry was used to detect the expressions of hMLH1, hMSH2 and hMSH6 in 96 cases of SCC specimens.The relationship between expression of the mismatch repair protein(MMR)and clinical pathological features and prognosis.Results: The deletion expression rate of hMLH1, hMSH2 and hMSH6 was 20.8%(20/96),8.3%(8/96),and 7.3%(7/96), respectively.The total deletion expression rate of MMR was 28.1%(27/96).The deletion expression of MMR was significantly related with pTNM stage, tumor site, tumor diameter, lymph node metastasis and gross type(P<0.05).The five-year disease-free survival rate was 77.8%(21/27)in the MMR deletion expression group and 46.4%(32/69)in the normal MMR group, and the difference was significant(χ2=8.955, P=0.003).The five-year overall survival rate was 85.2%(23/27)in the MMR deletion expression group and 49.3%(34/69)in the normal MMR group, and the difference was significant(χ2=12.009, P<0.001). The univariate and multivariate analysis showed that MMR status was risk factor influencing disease-free survival and overall survival time in patients with SCC.Conclusion: The young and middle-aged SCC patients with MMR deletion expression have better prognosis than those with normal MMR expression.

参考文献/References:

[1] DONNINELLI G,DEL CORN M,PIERDOMINICI MA,et al.Distinct blood and visceral adipose tissue regulatory T cell and innate lymphocyte profiles characterize obesity and colorectal cancer[J].Front Immunol,2017,8:643
[2] CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China, 2015[J].CA Cancer J Clin,2016,66(2):115
[3] HASHMI AA,ALI R,HUSSAIN ZF,et al.Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters[J].World J Surg Oncol,2017,15(1):116
[4] FARCHOUKH L,KUAN SF,DUDLEY B,et al.MLH1-deficient colorectal carcinoma with wild-type BRAF and MLH1 promoter hypermethylation harbor KRAS mutations and arise from conventional adenomas[J].Am J Surg Pathol,2016,40(10):1390
[5] LOTHE RA,PELTOMAKI P,MELING GI,et al.Genomic instability in colorectal cancer:relationship to clinicopathological variables and family history[J].Cancer Res,1993,53(24):5849
[6] SUZUKI S,IWAIZUMI M,TSENG-ROGENSKI SA,et al.Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status[J].Cancer Biol Ther,2016,17(7):760
[7] LI GX,HU FL,YUAN FS,et al.Intronic and promoter polymorphisms of hMLH1/hMSH2 and colorectal cancer risk in Heilongjiang Province of China[J].J Cancer Res Clin Oncol,2015,141(8):1393
[8] EDGE SB,COMPTON CC.The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Ann Surg Oncol,2010,17(6):1471
[9] 秦琼,应建明,吕宁,等.DNA错配修复与结肠癌预后和疗效预测的相关性[J].中华肿瘤杂志,2014,36(11):844
[10]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229
[11]SEIFERT M,REICHRATH J.The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer[J].J Mol Histol,2006,37(5/7):301
[12]WADA HO,YANO T,NEI T,et al.The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha[J].Br J Cancer,2005,92(12):2286
[13]MURESAN F,SIMESCU R,DOMSA I,et al.Immunohistochemical screening of hMLH1 and hMSH2 gene mutations in patients diagnosed with colorectal cancer and microsatellite instability suspicion[J].Chirurgia(Bucur),2011,106(6):775
[14]MEROK MA,AHLQUIST T,ROYRVIK EC,et al.Microsatellite instability has a positive prognostic impact on stage Ⅱ colorectal cancer after complete resection:results from a large,consecutive Norwegian series[J].Ann Oncol,2013,24(5):1274
[15]SINICROPE FA,SARGENT DJ.Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications[J].Clin Cancer Res,2012,18(6):1506
[16]KAUR G, MASOUD A, RAIHAN N, et al. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma[J]. Indian J Med Res, 2011,134:186
[17]GHANIPOUR L, JIRSTRÖM K,SUNDSTRÖM M,et al.Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer[J]. Eur J Surg Oncol,2017,43(2):311
[18]JASS JR,WALSH MD,BARKER M,et al.Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability[J].Eur J Cancer,2002,38(7):858
[19]APARICIO T,SCHISCHMANOFF O,POUPARDIN C,et al.Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients[J].Dig Liver Dis,2013,45(3):245
[20]BELLIZZI AM,FRANKEL WL.Colorectal cancer due to deficiency in DNA mismatch repair function a review[J].Adv Anat Pathol,2009,16(6):405
[21]PARK JW,CHANG HJ,PARK S,et al.Absence of hMLH1 or hMSH2 expression as a stage-dependent prognostic factor in sporadic colorectal cancers[J].Ann Surg Oncol,2010,17(11):2839
[22]SINICROPE FA,MAHONEY MR,SMYRK TC,et al.Prognostic impact of deficient DNA mismatch repair in patients with stage Ⅲ colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy[J].J Clin Oncol,2013,31(29):3664
[23]SINICROPE FA,FOSTER NR,THIBODEAU SN,et al.DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy[J].J Natl Cancer Inst,2011,103(11):863
[24]SARGENT D,SOBRERO A,GROTHEY A,et al.Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials[J].J Clin Oncol,2009,27(6):872
[25]SARGENT DJ,MARSONI S,MONGES G,et al.Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J].J Clin Oncol,2010,28(20):3219
[26]SCARPA M,RUFFOLO C,CANAL F,et al.Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance[J].Oncotarget,2015,6(41):43472
[27]WENDUM D,BOELLE PY,RIGAU V,et al.Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression[J].Virchows Archiv,2003,442(2):111
[28]TOURNIGAND C,ANDRRÉ T,BONNETAIN FA,et al.Adjuvant therapy with fluorouracil and oxaliplatin in stage Ⅱ and elderly patients(between ages 70 and 75 years)with colon cancer: subgroup analyses of the multicenter international study of Oxaliplatin, Fluorouracil, and Leucovorin in the adjuvant treatment of colon cancer trial[J].J Clin Oncol,2012,30(27):3353

相似文献/References:

[1]梁高峰),李俊生),何向峰),等.基于高通量测序的结直肠癌miRNA表达谱分析[J].郑州大学学报(医学版),2015,(05):618.
 LIANG Gaofeng)),LI Junsheng),HE Xiangfeng),et al.Analysis of miRNA expression profiles in colorectal cancer based on high-throughput sequencing[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2015,(02):618.
[2]郑 立△,史朝辉.低位梗阻性左半结直肠癌经肛肠梗阻导管清洗减压与术中结肠灌洗效果比较[J].郑州大学学报(医学版),2016,(04):552.
[3]罗真真),张 震),乔亚敏),等.萝卜硫素对结直肠癌SW620细胞增殖、凋亡及迁移的影响*[J].郑州大学学报(医学版),2017,(03):281.[doi:10.13705/j.issn.1671-6825.2017.03.010]
 LUO Zhenzhen),ZHANG Zhen),QIAO Yamin),et al.Effects of sulforaphane on proliferation,apoptosis and migration of SW620 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2017,(02):281.[doi:10.13705/j.issn.1671-6825.2017.03.010]
[4]刘继攀,孙 伟,赵学荣,等.miR-101对结直肠癌细胞增殖、凋亡及KIF14蛋白表达的影响[J].郑州大学学报(医学版),2018,(06):776.[doi:10.13705/j.issn.1671-6825.2018.11.003]
 LIU Jipan,SUN Wei,ZHAO Xuerong,et al.Effect of miR-101 on proliferation,apoptosis and KIF14 expression of colorectal cancer cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(02):776.[doi:10.13705/j.issn.1671-6825.2018.11.003]

备注/Memo

备注/Memo:
【基金项目】河南省科技攻关计划基金资助项目(201503099)
【作者简介】周英发,通信作者,男,1969年10月生,博士,副主任医师,研究方向:消化道肿瘤,E-mail:yfzhou69@163.com
更新日期/Last Update: 2018-03-20